Viyash Scientific reported record Q4 FY26 revenue of ₹9,200 Mn, a 19% YoY growth, driven by strong formulations performance.
EBITDA for the quarter surged 64% YoY to ₹2,001 Mn, with margins expanding to 21.7% from 15.8% in Q4 FY25.
The company completed its merger integration, realizing synergies in R&D, manufacturing, and procurement with 6 new products developed.
Management highlighted transformative FY26 with significant debt reduction and is evaluating selective inorganic growth opportunities for FY27.